Reversal of tamoxifen resistance of human breast carcinomas in Vivo by neutralizing antibodies to transforming growth factor-β

Journal of the National Cancer Institute

Volumn 91, Issue 1, 1999, Pages 46-53

  Arteaga, Carlos L ^a,b   Koli, Katri M ^b   Dugger, Teresa C ^b   Clarke, Robert ^c  

^a VANDERBILT INGRAM CANCER CENTER   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c GEORGETOWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEUTRALIZING ANTIBODY; TAMOXIFEN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CARCINOMA; CANCER IMMUNOTHERAPY; CANCER RESISTANCE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IMMUNOMODULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0033528058     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/91.1.46     Document Type: Article

References (56)

1. Roberts AB, Sporn MB. The transforming growth factor-βs. In: Roberts AB, Sporn MB, editors. Handbook of experimental pharmacology. Heidelberg (Germany): Springer-Verlag: 1990. p. 419-72.
2. Moses HL. The biological action of transforming growth factor β. In: Sara V, Hall K, Low H, editors. Growth factors from genes to clinical application. New York (NY): Raven Press; 1990. p. 141-55.
3. Shull MM, Ormsby I, Kier AB, Pawlowski S, Diebold RJ, Yin M, et al. Targeted disruption of the mouse transforming growth factor-β1 gene results in multifocal inflammatory disease. Nature 1992;359:693-9.
4. Sanford LP, Ormsby I, Gittenberger-de Groot AC, Sariola H, Friedman F, Boivin GP, et al. TGFβ2 knockout mice have multiple developmental detects that are non-overlapping with other TGFβ knockout phenotypes. Development 1997;124:2659-70.
5. Proetzel G, Pawlowski SA, Wiles MV, Yin MY, Boivin GP, Howles PN, et al. Transforming growth factor-β3 is required for secondary palate fusion. Nat Genet 1995;11:409-14.
6. Koli KM, Arteaga CL. Complex role of tumor cell TGF-βs on breast carcinoma progression. J Mammary Gland Biol Neopl 1996;1:373-80.
7. Pierce DF, Johnson MD, Matsui Y, Robinson SD, Gold LI, Purchio AF, et al. Inhibition of mammary duct development but not alveolar outgrowth during pregnancy in transgenic mice expressing active TGF-β1. Genes Dev 1993;7:2308-17.
8. Knabbe C, Lippman ME, Wakefield LM, Flanders KC, Kasid A, Derynck R. et al. Evidence that transforming growth factor-β is a hormonally regulated negative growth factor in human breast cancer cells. Cell 1987;48: 417-28.
9. 1 in human breast cancer in vivo following tamoxifen treatment. Cancer Res 1992;52:4261-4.
10. Koli KM, Ramsey TT, Ko Y, Dugger TC, Brattain MG, Arteaga CL. Blockade of transforming growth factor-β signaling does not abrogate antiestrogen-induced growth inhibition of human breast carcinoma cells. J Biol Chem 1997;272:8296-302.
11. Daly RJ, King RJB, Darbre PD. Interaction of growth factors during progression toward steroid independence in T-47-D human breast cancer cells. J Cell Biochem 1990;43:199-211.
12. Hermann ME, Katzenellenbogen B. Alterations in transforming growth factor-β production and cell responsiveness during the progression of MCF-7 human breast cancer cells to estrogen-autonomous growth. Cancer Res 1990;54:5867-74.
13. Thompson AM, Kerr DJ, Steel CM. Transforming growth factor β1 is implicated in the failure of tamoxifen therapy in human breast cancer. Br J Cancer 1991;63:609-14.
14. Arteaga CL, Carty-Dugger T, Moses HL, Hurd SD, Pietenpol JA. Transforming growth factor β1 can induce estrogen-independent tumorigenicity of human breast cancer cells in athymic mice. Cell Growth Differ 1993;4: 193-201.
15. 1 in breast tissues: a biologically active form of the small latent complex of TGF-β. Eur J Cancer 1996;32A:1566-73.
16. 1 associates with disease progression in human breast cancer. Cancer Res 1992;52:6949-52.
17. Brunner N, Boulay V, Fojo A, Freter CE, Lippman ME, Clarke R. Acquisition of hormone-independent growth in MCF-7 cells is accompanied by increased expression of estrogen-regulated genes but without detectable DNA amplifications. Cancer Res 1993;53:283-90.
18. Brunner N, Frandsen TL, Holst-Hansen C, Bei M, Thompson EW, Wakeling AE, et al. MCF-7/LCC2: a 4-hydroxytamoxifen resistant human breast cancer variant that retains sensitivity to the steroidal antiestrogen ICI 182,780. Cancer Res 1993;192:3:3229-32.
19. 1 during lymphocyte activation: A study with a monoclonal antibody-based ELISA. J Immunol 1990;145:1415-22.
20. Sambrook J, Fritsch EF, Maniatis TE. Molecular cloning: a laboratory manual. Cold Spring Harbor (NY): Cold Spring Harbor Laboratory; 1989.
21. Derynck R, Jarrett JA, Chen EY, Eaton DH, Bell JR, Assoian RK, et al. Human transforming growth factor-beta complementary DNA sequence and expression in normal and transformed cells. Nature 1985;316:701-5.
22. 2: cDNA cloning and sequence analysis. DNA 1988;7:1-8.
23. Danielson PE, Forss-Petter S, Brow MA, Calavetta L, Douglass J, Milner RJ, et al. p1B15: a cDNA clone of the rat mRNA encoding cyclophilin. DNA 1988;7:261-7.
24. Arteaga CL, Coffey RJ Jr, Dugger TC, McCutchen CM, Moses HL, Lyons RM. Growth stimulation of human breast cancer cells with anti-transforming growth factor β antibodies: evidence for negative autocrine growth regulation by transforming growth factor β. Cell Growth Differ 1990;1:367-74.
25. Lyons RM, Miller DA, Graycar JL, Moses HL, Derynck R. Differential binding of transforming growth factor-β1, -β2, and -β3 by fibroblasts and epithelial cells measured by affinity cross-linking of cell surface receptors. Mol Endocrinol 1991;2:1887-96.
26. Arteaga CL, Hurd SD, Winnier AR, Johnson MD, Fendly BM, Forbes JT. Anti-transforming growth factor (TGF)-β antibodies inhibit breast cancer cell tumorigenicity and increase mouse spleen natural killer cell activity. Implications for a possible role of tumor cell/host TGF-β interactions in human breast cancer progression. J Clin Invest 1993;92:2569-76.
27. Jachimczak P, Bogdahn U, Schneider J, Behl C, Meixensberger J, Apfel R, et al. The effect of transforming growth factor-β2-specific phosphorothioate-anti-sense oligodeoxynucleotides in reversing cellular immunosuppression in malignant glioma. J Neurosurg 1993;78:944-51.
28. Ruscetti F, Varesio L, Ochoa A, Ortaldo J. Pleiotropic effects of transforming growth factor-β on cells of the immune system. Ann N Y Acad Sci 1993;685:488-500.
29. 1. J Exp Med 1990;172: 1777-84.
30. Clarke R. Human breast cancer cell line xenografts as models of breast cancer. The immunobiologies of recipient mice and the characteristics of several tumorigenic cell lines. Breast Cancer Res Treat 1996;39:69-86.
31. Baral E, Nagy E, Berczi I. The effect of tamoxifen on the immune response. In: Kellen JE, editor. Tamoxifen: beyond the antiestrogen. Boston (MA): Birkhauser; 1996. p. 137-78.
32. Wiebe VJ, Osborne CK, Fuqua SA, DeGregorio MW. Tamoxifen resistance in breast cancer. Crit Rev Oncol Hematol 1993;14:173-88.
33. Clarke R, Brunner N. Acquired estrogen independence and antiestrogen resistance in breast cancer. Estrogen receptor driven phenotypes? Trends Endocrinol Metab 1996;7:25-35.
34. Arteaga CL, Dugger TC, Clarke R, Koli KM. Blockade of tumor cell transforming growth factor (TGF)-βs restores tamoxifen (tam) sensitivity to tam-resistant human breast cancer cells. Breast Cancer Res Treat 1996; 41:220A.
35. Kopp A, Schmahl M, Knabbe C. Transforming growth factor β2 (TGF-β2) levels in plasma of patients with metastatic breast cancer treated with tamoxifen. Cancer Res 1995;55:4512-5.
36. MacCallum J, Keen JC, Bartlett JMS, Thompson AM, Dixon JM, Miller WR. Changes in expression of transforming growth factor β mRNA isoforms in patients undergoing tamoxifen therapy. Br J Cancer 1996;74: 474-8.
37. Trinchieri G. Biology of natural killer cells. Adv Immunol 1989;47: 187-376.
38. Liao N, Bix M, Zijistra M, Jaenisch R, Raulet DH. MHC class I deficiency: susceptibility to natural killer (NK) cells and impaired NK activity. Science 1991;253:199-202.
39. Screpanti I, Santoni A, Gulino A, Herberman RB, Frati L. Estrogen and antiestrogen modulation of the levels of mouse natural killer activity and large granular lymphocytes. Cell Immunol 1987;106:191-202.
40. Mandeville R, Ghali SS, Chausseau JP. In vitro stimulation of human NK activity by an estrogen antagonist (tamoxifen) [letter]. Eur J Cancer Clin Oncol 1984;20:983-5.
41. Berry J, Green BJ, Matheson DS. Modulation of natural killer cell activity by tamoxifen in stage I post-menopausal breast cancer. Eur J Cancer Clin Oncol 1987;23:517-20.
42. Baral E, Nagy E, Berczi I. Modulation of natural killer cell-mediated cytotoxicity by tamoxifen and estradiol. Cancer 1995;75:591-9.
43. Gottardis MM, Wagner RJ, Borden EC, Jordan VC. Differential ability of antiestrogens to stimulate breast cancer cell (MCF-7) growth in vivo and in vitro. Cancer Res 1989;49:4765-9.
44. An T, Sood U, Pietruk T, Cummings G, Hashimoto K, Crissman JD. In situ quantitation of inflammatory mononuclear cells in ductal infiltrating breast carcinoma. Relation to prognostic parameters. Am J Pathol 1987;128: 52-60.
45. Akimoto M, Ishii H, Nakajima Y, Iwasaki H. Assessment of host immune response in breast cancer patients. Cancer Detect Prev 1987;9:311-7.
46. Horst HA, Homy HP. Characterization and frequency distribution of lymphoreticular infiltrates in axillary lymph node metastases of invasive ductal carcinoma of the breast. Cancer 1987;60:3001-7.
47. Maiche AG, Jekunen A, Rissanen P, Virkkunen P, Halavaara J, Turunen JP. Sudden tumour regression with enhanced natural killer cell accumulation in a patient with stage IV breast cancer. Eur J Cancer 1994;30A: 1642-6.
48. Baral E, Nagy E, Berczi I. Modulation of lymphokine-activated killer cell-mediated cytotoxicity by estradiol and tamoxifen. Int J Cancer 1996;66: 214-8.
49. Baral E, Nagy E, Berczi I. Target cells are sensitized for cytotoxic T-lymphocyte-mediated destruction by estradiol and tamoxifen. Int J Cancer 1994;58:64-8.
50. Albertini MR, Gibson DF, Robinson SP, Howard SP, Tans KJ, Lindstrom MJ, et al. Influence of estradiol and tamoxifen on susceptibility of human breast cancer cell lines to lysis by lymphokine-activated killer cells. J Immunother 1992;11:30-9.
51. Gagliardi A, Collins DC. Inhibition of angiogenesis by antiestrogens. Cancer 1994;53:533-5.
52. Haran EF, Maretzek AF, Goldberg I, Horowitz A, Degani H. Tamoxifen enhances cell death in implanted MCF7 breast cancer by inhibiting endothelium growth. Cancer Res 1994;54:5511-4.
53. McLeskey SW, Kurebayashi J, Honig SF, Zwiebel J, Lippman ME, Dickson RB, et al. Fibroblast growth factor 4 transfection of MCF-7 cells produces cell lines that are tumorigenic and metastatic in ovariectomized or tamoxifen-treated athymic nude mice. Cancer Res 1993;53:2168-77.
54. Zhang L, Kharbanda S, Chen D, Bullocks J, Miller DL, Ding IY, et al. MCF-7 breast carcinoma cells overexpressing FGF-1 form vascularized, metastatic tumors in ovariectomized or tamoxifen-treated nude mice. Oncogene 1997;15:2093-108.
55. Zhang L, Kharbanda S, Hanfelt J, Kern FG. Both autocrine and paracrine effects of transfected acidic fibroblast growth factor are involved in the estrogen-independent and antiestrogen-resislant growth of MCF-7 breast cancer cells. Cancer Res 1998;58:352-61.
56. Roberts AB, Sporn MB, Assoian RK, Smith JM, Roche NS, Wakefield LM, et al. Transforming growth factor type β: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. Proc Natl Acad Sci U S A 1986;83:4167-71.